Evidence map›Paper›PMID 25179731›Full record

Trial reportLeukemia2014

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.

U Platzbecker, M A Sekeres, H Kantarjian, A Giagounidis, G J Mufti, C Jia, A S Yang, P Fenaux

Registry-linked trialAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00614523 (A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00614523 phase2completednot on this map

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

TypeinterventionalSponsorAmgenRan2008 to 2015Enrolled250ConditionsMDS, Myelodysplastic Syndromes, ThrombocytopeniaArmsPlacebo, Romiplostim
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

U PlatzbeckerUniversity Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany.
M A SekeresLeukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
H KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
A GiagounidisClinic for Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf, Düsseldorf, Germany.
G J MuftiKing's College London, London, UK.
C JiaAmgen Inc., South San Francisco, CA, USA.
A S YangAmgen Inc., Thousand Oaks, CA, USA.
P FenauxService d'hématologie clinique, Hopital Avicenne Universite Paris XIII, Bobigny, France.

Funding

Medical Research Council MR/J006742/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Platelet CountHumansMyelodysplastic SyndromesReceptors, FcRecombinant Fusion ProteinsThrombocytopeniaThrombopoietinTreatment OutcomeReceptors, FcRecombinant Fusion ProteinsromiplostimThrombopoietin

Identifiers

PMID25179731
PMCPMC4274610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.